| Active substance | secukinumab |
| Holder | Novartis Pharma NV |
| Status | closed |
| Indication | Treatment of active moderate to severe hidradenitis suppurativa |
| Public documents | Approbation |
| Information for the patient | |
| Informed consent | |
| Last update | 01/12/2023 |
Cosentyx
Last updated on 11/10/2024